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or to refine the decision formulation if uncertainty is high, potentially leading to 
improved decision-making.
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IntroductIon: The three main novel anticoagulants (NOACs) currently licensed 
in Europe, apixaban, dabigatran and rivaroxaban, have all been directly compared 
against warfarin in randomised controlled trials. However, none of the three drugs 
have been directly compared against each other. Thus, there has been an increase 
in the number of meta-analyses and indirect comparisons published comparing 
the relative efficacy and safety of these novel anticoagulants against each other 
via warfarin as a common comparator. objectIves: Systematically review all 
meta-analyses and indirect comparisons evaluating the NOACs against warfarin 
for the prevention of stroke in patients with AF and critically appraise the statistical 
methods used to do so. Methods: Systematic searches of EMBASE, MedLine, EBM 
Reviews, EconLIT as well as manual searches of ClincalTrials. gov, the Cochrane 
Library, CADTH, NICE, NHSEED and HTA were conducted. Data was abstracted from 
any citation applying statistical methods to compare the efficacy and safety of 
NOACs for the prevention of AF-related stroke. Information regarding the statistical 
approach; model assumptions; data presentation; interpretation of the evidence; 
and discussions of internal and external validity was used to quality rate each 
study. results: Bucher’s method of adjusted indirect comparison was most widely 
used. There were generally three main model assumptions required: the similarity, 
homogeneity and consistency assumptions, each being investigated with varying 
scrutiny in the studies reviewed. According to the quality assessment, the indirect 
comparison conducted by Wells and colleagues (2012) is of the highest relative qual-
ity. conclusIons: The limited number of RCTs available comparing the NOACs to 
standard therapy, creates considerable uncertainty surrounding the comparative 
efficacy and safety of these anticoagulants. In order to establish which individual 
NOAC is most likely to benefit a given patient population, indirect comparisons and 
meta-analyses are increasingly used. However, the quality of indirect comparison 
studies are variable and results should be interpreted with care.
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objectIves: Matching-adjusted indirect comparison (MAIC) is a novel comparative 
effectiveness approach to address biases that can appear in traditional indirect 
comparison (IC) methods when patient characteristics differ across trials. We exam-
ined three unanswered MAIC methodological questions and applied the proposed 
solutions to a comparison of ADHD treatments. Methods: Using individual patient 
data from two randomized controlled trials (RCTs) comparing guanfacine (GXR) 
vs placebo and published summary statistics from four RCTs comparing atomox-
etine (ATX) vs placebo, MAIC was used to reweight the GXR data so that observable 
GXR patient characteristics matched those of ATX patients. Change in ADHD-RS-IV 
scores was the primary endpoint. Comparative efficacy results were evaluated for 
their sensitivity to changes in the following three MAIC specifications: variable 
selection using regression-based methods, statistical moments matched (i.e., mean 
vs mean and variance), and matching on placebo-arm outcomes. results: Both 
treatments decreased ADHD-RS-IV scores relative to placebo (-17.9 GXR vs -10.7 
placebo; -14.6 ATX vs -5.8 placebo). In the baseline MAIC specification adjusting for 
patient baseline characteristics and placebo arm outcomes, GXR produced larger 
decreases in ADHD-RS-IV scores than ATX (Δ : -3.9, p< 0.004). The results were insen-
sitive to adding variables to the matching algorithm (Δ : -3.8, p< 0.023), or match-
ing only covariate means rather than both means and variances (Δ : -3.6, p< 0.006). 
Applying MAIC without matching placebo arm outcomes indicated a slightly greater 
decrease in ADHD-RS-IV scores for ATX, but there was no statistically significant 
difference between GXR and ATX (Δ : 0.6, p< 0.649). conclusIons: In this study, 
MAIC results were insensitive to variable selection via regression and the statistical 
moments matched, but matching the placebo arms altered the results. Matching 
placebo arm outcomes is valid when unobserved trial-specific factors have a dif-
ferential impact on a trial’s treatment and control arm outcomes; this was likely 
the case in this GXR-ATX study.
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objectIves: To develop a checklist to assess the quality of a network meta-analysis 
(NMA) in the context of a submission to NICE. This checklist is intended to be com-
prehensible and easy-to-use by non-statisticians to assess whether an NMA is suit-
able for a submission to NICE and/or to populate cost-effectiveness models within 
the context of the NICE requirements. Methods: An ad-hoc search of the literature 
was conducted to identify existing checklists. Items from these checklists were 
extracted and critically reviewed. Recommendations from NICE as well as existing 
NICE submissions and corresponding comments from the evidence review groups 
(ERG) were used to develop the checklist. Our checklist was validated by health 
economists and pharmacists not trained in NMA on the basis of a NICE submission 
to promote awareness on the medications, balanced diet and physical activity to 
improve the quality of life of an individual.
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objectIves: Treatment switching commonly occurs in the pivotal HTA evidence 
for advanced or metastatic cancer treatments submitted to reimbursement agen-
cies. Simple approaches, such as Intention-to-treat (ITT) analysis, have typically 
been used to analyse data with treatment switching, despite simulation studies 
showing these to drastically underestimate the underlying treatment effect. With 
more manufacturers conducting indirect comparisons (ICs) to compare treatments, 
summary data are being used more in analysis. The method outlined addresses 
treatment switching when only summary data are available to ensure appropri-
ate estimates for the treatment effect are achieved when the data is then used 
in an IC. Methods: Using digitised survival curves, multiple datasets that are 
representative of the original individual patient data (IPD) are simulated. Treatment 
switching information is estimated from reported information on progression-free 
survival, and then established methods which adjust appropriately for treatment 
switching used to analyse the simulated data. This approach is applied to an exam-
ple from a technology appraisal (TA) submitted to National Institute for Health and 
Care Excellence (NICE), and the ITT hazard ratio and median survival obtained and 
compared with those reported, before analysis using a Rank Preserving Structural 
Failure Time Model (RPSFTM). results: Averaging over 2000 datasets, the replicated 
summary statistics were similar to those reported. Both median survival times were 
within 1 month of those stated in the TA and the hazard ratio less than 0.05 differ-
ent. Subsequent analysis using an RPSFTM shows the new treatment to be more 
effective, and inappropriately adjusting for crossover to have underestimated the 
treatment effect. conclusIons: Adjusting summary data is important as other-
wise, subsequent analysis conducted will give inappropriate results. The simulated 
data approach well represents the original IPD, giving on average similar results to 
those reported. Hence, the further analysis to address treatment switching issues 
gives more appropriate treatment effect estimates.
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objectIves: To estimate the impact of combining the dipeptidyl peptidase-4 (DPP-
4) inhibitor, alogliptin, with metformin and sulfonylurea (alogliptin triple therapy) 
to achieve glycemic control in patients with type 2 diabetes. Methods: Since no 
clinical trial of alogliptin triple therapy has been conducted, the effect of adding 
alogliptin to dual therapy (metformin+sulfonylurea) was modeled using novel addi-
tive effect methodology, utilizing data from a previous mixed treatment comparison 
(MTC). The following assumptions were made: the efficacy of triple therapy can be 
estimated as a function of its constituent parts, and the efficacies of the constituent 
parts are equivalent. Pooled data for the absolute change from baseline in glyco-
sylated hemoglobin (HbA1c) from trials of sitagliptin, linagliptin, and vildagliptin 
triple therapy, and for their constituent parts, informed the model. A weighting fac-
tor, β coefficient, derived from DPP-4 mono, dual, and triple therapy trials, was used 
to estimate the effect size for triple therapy using the sum of the constituent parts. 
The estimated mean β value was validated against the observed effect size of alog
liptin+pioglitazone+metformin, using the pooled effect from the MTC. results: 
An estimated mean β coefficient value of 0.83 represented the DPP-4 inhibitor class. 
Validation of the approach resulted in a similar β coefficient for pioglitazone triple 
therapy (0.82). Absolute change in HbA1c from baseline for alogliptin triple therapy 
was estimated as -0.77% (95% CI -1.16, -0.39). Similar values were observed in the 
MTC for sitagliptin -0.94% (95% CI -7.34,5. 40), linagliptin -0.65 (95% CI -6.87,5. 60), 
and vildagliptin -0.80% (95% CI -7.00,5. 43). conclusIons: The wide confidence 
interval is consistent with expectations in the literature and is a limitation of the 
method employed, in that it requires the variance of the individual studies to be 
summated. Nevertheless, the method demonstrates the value of modeling when 
clinical trial evidence is not available.
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objectIves: Multi-Criteria Decision Analysis (MCDA) is a collection of techniques 
for choosing optimal decisions when two or more criteria need to be taken into 
account in the decision process. Most MCDA techniques require the specification 
of a number of parameters; criteria weights, utility functions or indifference thresh-
olds. We wish to account for the uncertainty in these parameters which may arise 
due to the fuzzy nature of the Decision Maker’s preferences, conflicting opinions 
between a group of decision makers or population group, or the abstract nature of 
the parameters. Methods: We implement some MCDA models from a Bayesian 
perspective where parameters come from posterior probability distributions repre-
senting the combination of available knowledge on the parameters. Such knowledge 
can come from empirical data, expert elicitation, survey data, decision-making com-
mittees, or some combination of these. results: Depending on the method used, 
the end result is either a benefit function which quantifies the uncertainty in the 
benefit score for each action, or a rankogram which depicts the uncertainty in the 
ranking of actions. conclusIons: Knowledge about this uncertainty allows deci-
sion makers to make more informed decisions. A decision action may be clear when 
uncertainty is sufficiently low, or it may be necessary to request more information 
